Formulations of alpha-amylase inhibitors with alpha-glucosidase inhibitors useful in the treatment of diabetes and obesity
US7553502B2 · kind B2 · utility
2Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2008 |
| Grant date | Jun 30, 2009 |
| Priority date | — |
| Expiry date | Mar 5, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K36/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the combination of α-amylase inhibitors prepared from Phaseolus vulgaris with α-glucosidase inhibitors obtained from Salacia oblonga and other species. The α-amylase inhibitor is accompanied by a quantity of lectins that reduces the amount of glucose originating from the starches present in the diet, and considerably reduces the appetite after repeated administration. The combination with α-glucosidase inhibitors, such as extracts of Salacia or the thiosugars present in it, further reduce the blood glucose, acting synergically, and consequently reduce the synthesis of fats from carbohydrates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.